Nutex Health (NUTX) Expected to Post Earnings on Thursday

Nutex Health (NASDAQ:NUTX) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Nutex Health to announce earnings of $4.95 per share and revenue of $215.0310 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 10:30 AM ET.

Nutex Health Price Performance

Shares of NUTX stock opened at $152.93 on Tuesday. Nutex Health has a fifty-two week low of $77.21 and a fifty-two week high of $204.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.12 and a current ratio of 3.14. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 11.82 and a beta of 0.24. The stock’s 50-day simple moving average is $154.70 and its 200-day simple moving average is $129.08.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its stake in shares of Nutex Health by 966.7% in the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after buying an additional 290 shares in the last quarter. Royal Bank of Canada grew its stake in Nutex Health by 752.4% during the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after acquiring an additional 316 shares in the last quarter. Osaic Holdings Inc. grew its stake in Nutex Health by 280.3% during the 4th quarter. Osaic Holdings Inc. now owns 810 shares of the company’s stock valued at $133,000 after acquiring an additional 597 shares in the last quarter. Vestcor Inc acquired a new stake in Nutex Health in the 3rd quarter valued at about $111,000. Finally, New York State Common Retirement Fund acquired a new stake in Nutex Health in the 2nd quarter valued at about $137,000. 5.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NUTX. Weiss Ratings raised shares of Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. Lake Street Capital began coverage on shares of Nutex Health in a research note on Tuesday, June 2nd. They set a “buy” rating and a $235.00 price objective for the company. B. Riley Financial assumed coverage on shares of Nutex Health in a report on Friday, June 26th. They issued a “buy” rating and a $290.00 price objective on the stock. Wall Street Zen lowered shares of Nutex Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Zacks Research raised shares of Nutex Health to a “hold” rating in a report on Monday, June 29th. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Nutex Health currently has a consensus rating of “Moderate Buy” and an average price target of $243.33.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.